Evidence map›Paper›PMID 25328665›Full record

ArticleCell & bioscience2014

Absence of Appl2 sensitizes endotoxin shock through activation of PI3K/Akt pathway.

Liufeng Mao, Wanhua Lin, Tao Nie, Xiaoyan Hui, Xuefei Gao, Kuai Li, Mengxiao Ding, Xiaofeng Tang, Peng Li, Yu Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell & bioscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Lack ofGenes · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Adiponectin signaling and function in insulin target tissues.Journal of molecular cell biology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Liufeng MaoKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Wanhua LinSchool of Life Sciences, Guangxi Normal University, Guilin, 541004 China ; Lab for Stem Cell and Pharmaceutical Biotechnology of Guangxi Normal University, Guilin, 541004 China.
Tao NieKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Xiaoyan HuiState key laboratory of pharmaceutical biotechnology, Department of Medicine, The University of Hong Kong, Hong Kong, 999077 China.
Xuefei GaoWellcome Trust Sanger Institute, Cambridge, CB10 1SA UK.
Kuai LiKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Mengxiao DingKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Xiaofeng TangKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Peng LiKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Yu WangState key laboratory of pharmaceutical biotechnology, Department of Medicine, The University of Hong Kong, Hong Kong, 999077 China.
Aimin XuState key laboratory of pharmaceutical biotechnology, Department of Medicine, The University of Hong Kong, Hong Kong, 999077 China.
Pentao LiuWellcome Trust Sanger Institute, Cambridge, CB10 1SA UK.
Donghai WuKey Laboratory of Regenerative Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.
Chinese Academy of Sciences · CNUniversity of Hong Kong · HKGuangzhou Institutes of Biomedicine and Health · CNWellcome Sanger Institute · GBGuangxi Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe adapter proteins Appl1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine domain, and leucine zipper motif 1) and Appl2 are highly homologous and involved in several signaling pathways. While previous studies have shown that Appl1 plays a pivotal role in adiponectin signaling and insulin secretion, the physiological functions of Appl2 are largely unknown.

resultsIn the present study, the role of Appl2 in sepsis shock was investigated by using Appl2 knockout (KO) mice. When challenged with lipopolysaccharides (LPS), Appl2 KO mice exhibited more severe symptoms of endotoxin shock, accompanied by increased production of proinflammatory cytokines. In comparison with the wild-type control, deletion of Appl2 led to higher levels of TNF-α and IL-1β in primary macrophages. In addition, phosphorylation of Akt and its downstream effector NF-κB was significantly enhanced. By co-immunoprecipitation, we found that Appl2 and Appl1 interacted with each other and formed a complex with PI3K regulatory subunit p85α, which is an upstream regulator of Akt. Consistent with these results, deletion of Appl1 in macrophages exhibited characteristics of reduced Akt activation and decreased the production of TNFα and IL-1β when challenged by LPS.

conclusionsResults of the present study demonstrated that Appl2 is a critical negative regulator of innate immune response via inhibition of PI3K/Akt/NF-κB signaling pathway by forming a complex with Appl1 and PI3K.

Indexed as

AktAppl1Appl2Endotoxin shockInflammatory cytokinesNF-κBPI3K

Identifiers

PMID25328665
PMCPMC4201708
OpenAlexW2149987245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.